Philadelphia – Two esteemed leaders from the University of Pennsylvania’s Penn Medicine Abramson Cancer Center and Perelman College of Medicine have been honored with the 2023 Special Award from the American Society of Clinical Oncology (ASCO) and ASCO Foundation, Conquer Cancer, during the 2023 ASCO period. Prizes will be awarded. The Annual Meeting will be held June 2-6 in Chicago, Illinois.
Angela DeMichel, M.D., M.Sc.Jill & Alan Miller Endowed Professors of Breast Cancer Excellence, co-leaders of the Breast Cancer Research Program at Abramson Cancer Center, and co-directors of the 2-PREVENT Breast Cancer Translational Center of Excellence are 2023 recipients. Gianni Bonadonna Breast Cancer Award. Carmen E. Guerra, MD, MSc, FACPRuth C. Perelman and Raymond G. Perelman, Professor of Medicine, Vice Chairs of Diversity and Inclusion at the School of Medicine and Vice Directors of Diversity and Outreach at Abramson Cancer Center, Recipients of 2023 ASCO Excellence in Equity Awards is a person. .
“Dr. Guerra and Dr. De Michelle are delighted to be recognized for their impactful contributions to equity in cancer care and breast cancer research,” said Dr. Dr. Robert Vonderheide, Ph.D., Director of Abramson Cancer Center. “Through their research and community support and engagement, from the clinical setting to the bedside, their work has made a difference for cancer patients and families across the country and in our communities. I am very grateful.”
Angela DeMichel, M.D., M.Sc., Gianni Bonadonna Breast Cancer Award
The Gianni Bonadonna Breast Cancer Award was created to honor Dr. Gianni Bonadonna for several pioneering contributions to the field of oncology. The award recognizes active clinical and/or translational researchers who have demonstrated outstanding achievement and leadership in advancing the field of breast cancer. Demichel was instrumental in the development of one of his first CDK4/6 inhibitors, palbociclib, a type of targeted therapy drug used to treat certain types of his HR-positive and HER2-negative breast cancer. Known for their role. As a physician and scientist, her research focuses on developing experimental therapies, investigating prognostic and predictive biomarkers, and designing new approaches to identify and treat minimal residual disease to prevent breast cancer from recurring. Emphasis. The 2-PREVENT Breast Cancer Translational Center of Excellence, which she co-directs at Abramson Cancer Center, identifies resting or ‘sleeper’ cells that may persist after initial breast cancer treatment through innovative clinical trials and focus on treatment. She has held leadership roles in numerous national oncology groups, including her ECOG-ACRIN and her I-SPY consortium, and is the incoming Chair of the ASCO Scientific Programs Committee.
Mr. De Michelle’s award speech will be available online for attendees to view on demand.
Carmen E. Guerra, MD, MSCE, FACP, Excellence in Equity Award
ASCO Excellence in Equity Award, presented by the American Cancer Society, for outstanding and measurable contributions towards improving equity, diversity and inclusion in the field of oncology or increasing access to equitable care for cancer patients This award recognizes ASCO members who have Guerra is known for its tenacious work to promote equitable access to cancer clinical trials, cancer screening and care. She has led the development of several cancer screening patient navigation programs, including the Flu-FIT program. The program, which began as a drive-thru event during the COVID-19 pandemic, allows attendees to receive both a flu shot and her FIT kit. At-home colon cancer screening. She also established a community outreach and engagement program to increase participation of black patients in cancer clinical trials, resulting in an increase in the percentage of black participants enrolled in clinical trials at Abramson Cancer Center. Twice as much as her. As co-chair of two of her workgroups at ASCO and the Association of Regional Cancer Centers, Guerra contributed to developing unconscious bias training and self-assessments on equity, diversity and inclusion for cancer research teams. .
Mr. Guerra will participate in a mentorship and career development roundtable discussion with ASCO’s Special Award Winners on Sunday, June 4 at S103 at 10:00 am Central Time.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to medical education, biomedical research, and related missions of excellence in patient care. Pen medicine consists of: University of Pennsylvania Raymond Perelman and Ruth Perelman School of Medicine (Established in 1765 as the first medical school in Japan) University of Pennsylvania Health Systemtogether forming a $9.9 billion company.
Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to a survey of research-oriented medical schools by U.S. News & World Report. The school consistently ranks among the top in the nation for funding from the National Institutes of Health, with $546 million awarded in fiscal 2021.
The patient care facilities of the University of Pennsylvania Health System include the University of Pennsylvania Hospital and Penn Presbyterian Medical Center. These are Chester County Hospitals, recognized by US News & World Report as one of the nation’s top “honored” hospitals. Lancaster General Health; Penn Medicine Princeton Health. Other facilities and companies include Good Shepherd Pen Partners, Pen Medicine at Home, Lancaster Behavioral Health Hospital and Princeton House Behavioral Health.
Penn Medicine is powered by over 47,000 talented and dedicated employees. The organization also partners with top community health systems in both southeastern Pennsylvania and southern New Jersey, creating more options for patients wherever they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal 2021, Pen Medicine provided more than $619 million to benefit the community.